Your browser doesn't support javascript.
loading
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Hurkmans, Daan P; Verdegaal, Els M E; Hogan, Sabrina A; de Wijn, Rik; Hovestad, Lies; van den Heuvel, Dianne M A; Ruijtenbeek, Rob; Welters, Marij J P; van Brakel, Mandy; Basak, Edwin A; Pinedo, Herbert M; Lamers, Cor H J; van de Werken, Harmen J G; Groten, John P; Debets, Reno; Levesque, Mitchell P; Dummer, Reinhard; Kapiteijn, Ellen; Mathijssen, Ron H J; Aerts, Joachim G J V; van der Burg, Sjoerd H.
Afiliación
  • Hurkmans DP; Department of Pulmonology, Erasmus University Medical Center, Rotterdam, The Netherlands d.hurkmans@erasmusmc.nl shvdburg@lumc.nl.
  • Verdegaal EME; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Hogan SA; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
  • de Wijn R; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Hovestad L; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands.
  • van den Heuvel DMA; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands.
  • Ruijtenbeek R; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands.
  • Welters MJP; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands.
  • van Brakel M; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
  • Basak EA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Pinedo HM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Lamers CHJ; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands.
  • van de Werken HJG; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Groten JP; Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Debets R; Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Levesque MP; PamGene International B.V, HH 's-Hertogenbosch, The Netherlands.
  • Dummer R; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Kapiteijn E; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Mathijssen RHJ; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Aerts JGJV; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • van der Burg SH; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
J Immunother Cancer ; 8(2)2020 12.
Article en En | MEDLINE | ID: mdl-33427690
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Inmunoterapia / Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Inmunoterapia / Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido